BRCA1 and breast carcinoma: All trials that explore the efficacy of PARPi in high-penetrance risk genes (BRCA1/2, PALB2) have shown activity in those genes, definitely introducing in the metastatic breast cancer therapeutic algorithm a new standard treatment for germline mutation carriers.